One kind of immune cell helps another stay active for years against invaders, a finding that could lead to therapies…
Articles by Inês Martins, PhD
The U.S. Food and Drug Administration has approved the anti-CD20 therapy Revlimid (lenalidomide) as a maintenance therapy for multiple…
Multiple myeloma (MM) patients treated at facilities that handle more patients may have better survival rates than those treated at…
The first multiple myeloma patient has enrolled in a trial of Celyad‘s T-cell therapy for seven types of cancer that have…
A man who calls himself a Hollyweed artist has started an Indiegogo crowdfunding campaign to create T-shirts marking California’s legalization…
Patients with smoldering multiple myeloma (SMM), an asymptomatic form of myeloma, do not benefit from treatment with the anti-ICAM1 antibody…
A Phase 1 trial will soon be assessing Actimab-M, an anti-CD33 antibody bound to a radioactive compound, in heavily treated multiple myeloma…
People with chronic diseases value the Affordable Care Act (ACA), commonly known as Obamacare, more than Americans in general, a survey…
The use of Revlimid (lenalidomide) as a maintenance therapy for adult patients with newly diagnosed multiple myeloma who underwent…
Cellectar Biosciences has been granted a U.S. patent for the method of use for the compounds CLR 131 and CLR…